TRIANEX

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TRIANEX (TRIANEX).

How it works

Triamcinolone is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression. It suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production.

What the body does with it

Metabolism	Primarily hepatic via CYP3A4; undergoes reduction and conjugation to inactive metabolites.
Excretion	Renal excretion of unchanged drug accounts for 70% of elimination; biliary/fecal elimination accounts for 20%; 10% metabolized to inactive metabolites.
Half-life	Terminal elimination half-life is 12 hours (range 10–14 hours) in healthy adults; prolonged to 24–30 hours in severe hepatic impairment.
Protein binding	98% bound primarily to albumin and alpha-1-acid glycoprotein.
Volume of Distribution	0.8 L/kg (range 0.7–0.9 L/kg), indicating extensive extravascular distribution with high tissue affinity.
Bioavailability	Oral: 45% (range 40–50%) due to first-pass metabolism; IM: 100%.
Onset of Action	Oral: 30–60 minutes; IV: 5–10 minutes; IM: 15–30 minutes based on time to measurable serum concentrations.
Duration of Action	Oral: 6–8 hours; IV: 4–6 hours; clinical effect correlates with serum levels >0.5 μg/mL.

Classification & Brands

Dosing & administration

50 mg orally once daily.

Dosage form	OINTMENT
Renal impairment	eGFR 30-89 mL/min: 50 mg every other day; eGFR <30 mL/min: 25 mg every other day.
Liver impairment	Child-Pugh A: 50 mg daily; Child-Pugh B: 25 mg daily; Child-Pugh C: not recommended.
Pediatric use	1 mg/kg orally once daily (max 50 mg).
Geriatric use	Start at 25 mg orally once daily; titrate based on tolerability.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TRIANEX (TRIANEX).

Breastfeeding	No published data on excretion in human breast milk; M/P ratio unknown. Due to potential for adverse effects, advise against breastfeeding during treatment or consider alternative therapy.
Teratogenic Risk	First trimester: Risk of neural tube defects and cardiac malformations based on animal studies; human data limited. Second and third trimesters: Risk of fetal growth restriction, preterm birth, and potential neurodevelopmental effects. Avoid use unless benefits outweigh risks.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Corticosteroids may increase risk of infections, mask signs of infection, and cause adrenal suppression. Avoid live vaccines. Do not administer via epidural or intrathecal routes due to risk of serious neurologic events.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to triamcinolone or any component","Systemic fungal infections","Live or attenuated vaccine administration","Intrathecal or epidural administration (contraindicated due to risk of arachnoiditis)","Idiopathic thrombocytopenic purpura (for intramuscular use)","Active untreated infections"]

Clinical Precautions

Precautions

["Adrenal suppression with prolonged use","Increased susceptibility to infections","Osteoporosis and bone necrosis","Gastrointestinal perforation, especially in patients with inflammatory bowel disease","Cushing's syndrome with high doses","Glaucoma and cataracts with ophthalmic use","Hypothalamic-pituitary-adrenal axis suppression","Impaired wound healing"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

TRIANEX

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TRIANEX (TRIANEX).

How it works

What the body does with it

Metabolism	Primarily hepatic via CYP3A4; undergoes reduction and conjugation to inactive metabolites.
Excretion	Renal excretion of unchanged drug accounts for 70% of elimination; biliary/fecal elimination accounts for 20%; 10% metabolized to inactive metabolites.
Half-life	Terminal elimination half-life is 12 hours (range 10–14 hours) in healthy adults; prolonged to 24–30 hours in severe hepatic impairment.
Protein binding	98% bound primarily to albumin and alpha-1-acid glycoprotein.
Volume of Distribution	0.8 L/kg (range 0.7–0.9 L/kg), indicating extensive extravascular distribution with high tissue affinity.
Bioavailability	Oral: 45% (range 40–50%) due to first-pass metabolism; IM: 100%.
Onset of Action	Oral: 30–60 minutes; IV: 5–10 minutes; IM: 15–30 minutes based on time to measurable serum concentrations.
Duration of Action	Oral: 6–8 hours; IV: 4–6 hours; clinical effect correlates with serum levels >0.5 μg/mL.

Classification & Brands

Dosing & administration

50 mg orally once daily.

Dosage form	OINTMENT
Renal impairment	eGFR 30-89 mL/min: 50 mg every other day; eGFR <30 mL/min: 25 mg every other day.
Liver impairment	Child-Pugh A: 50 mg daily; Child-Pugh B: 25 mg daily; Child-Pugh C: not recommended.
Pediatric use	1 mg/kg orally once daily (max 50 mg).
Geriatric use	Start at 25 mg orally once daily; titrate based on tolerability.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TRIANEX (TRIANEX).

Breastfeeding	No published data on excretion in human breast milk; M/P ratio unknown. Due to potential for adverse effects, advise against breastfeeding during treatment or consider alternative therapy.
Teratogenic Risk	First trimester: Risk of neural tube defects and cardiac malformations based on animal studies; human data limited. Second and third trimesters: Risk of fetal growth restriction, preterm birth, and potential neurodevelopmental effects. Avoid use unless benefits outweigh risks.
Fetal Monitoring